Viatris Inc. (VTRS) posted a third quarter net loss of $128.2 million or $0.11 per share compared to net income of $94.8 million or $0.08 per share, prior year. The company noted that the loss in the current quarter was primarily driven by a reduction in the fair value of the investment in the compulsory convertible preferred shares of Biocon Biologics and an increase in income tax expense.
Adjusted net earnings declined to $784.3 million or $0.67 per share from $897.6 million or $0.75 per share. Analysts on average expected the company to report profit per share of $0.62, for the quarter. Analysts' estimates typically exclude special items.
Total revenues increased to $3.76 billion from $3.75 billion, last year. Excluding the Indore Impact, divestiture-adjusted operational total revenues increased 1% compared to third quarter 2024.
For 2025, the company now expects adjusted EPS in a range of $2.25 - $2.35, revised from prior guidance range of $2.16 - $2.30. Total revenues are now projected in a range of $13.9 - $14.3 billion, revised from prior guidance range of $13.5 billion - $14.0 billion.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.